Literature DB >> 33264572

Opposing Roles of Type I Interferons in Cancer Immunity.

Giselle M Boukhaled1,2, Shane Harding1,2,3, David G Brooks1,2.   

Abstract

The immune system is tasked with identifying malignant cells to eliminate or prevent cancer spread. This involves a complex orchestration of many immune cell types that together recognize different aspects of tumor transformation and growth. In response, tumors have developed mechanisms to circumvent immune attack. Type I interferons (IFN-Is) are a class of proinflammatory cytokines produced in response to viruses and other environmental stressors. IFN-Is are also emerging as essential drivers of antitumor immunity, potently stimulating the ability of immune cells to eliminate tumor cells. However, a more complicated role for IFN-Is has arisen, as prolonged stimulation can promote feedback inhibitory mechanisms that contribute to immune exhaustion and other deleterious effects that directly or indirectly permit cancer cells to escape immune clearance. We review the fundamental and opposing functions of IFN-Is that modulate tumor growth and impact immune function and ultimately how these functions can be harnessed for the design of new cancer therapies.

Entities:  

Keywords:  IFN-I; IFN-stimulated gene; ISG; cancer immunology; hallmarks of cancer; immunotherapy; type I interferon

Mesh:

Substances:

Year:  2020        PMID: 33264572      PMCID: PMC8063563          DOI: 10.1146/annurev-pathol-031920-093932

Source DB:  PubMed          Journal:  Annu Rev Pathol        ISSN: 1553-4006            Impact factor:   23.472


  216 in total

1.  IFN-{beta} signaling positively regulates tumorigenesis in aggressive fibromatosis, potentially by modulating mesenchymal progenitors.

Authors:  Sean S Tjandra; Claire Hsu; Y Ingrid Goh; Ingrid Goh; Ananta Gurung; Raymond Poon; Puviindran Nadesan; Benjamin A Alman
Journal:  Cancer Res       Date:  2007-08-01       Impact factor: 12.701

2.  Type I IFN contributes to NK cell homeostasis, activation, and antitumor function.

Authors:  Jeremy B Swann; Yoshihiro Hayakawa; Nadeen Zerafa; Kathleen C F Sheehan; Bernadette Scott; Robert D Schreiber; Paul Hertzog; Mark J Smyth
Journal:  J Immunol       Date:  2007-06-15       Impact factor: 5.422

3.  Inactivation of Interferon Receptor Promotes the Establishment of Immune Privileged Tumor Microenvironment.

Authors:  Kanstantsin V Katlinski; Jun Gui; Yuliya V Katlinskaya; Angelíca Ortiz; Riddhita Chakraborty; Sabyasachi Bhattacharya; Christopher J Carbone; Daniel P Beiting; Melanie A Girondo; Amy R Peck; Ellen Puré; Priya Chatterji; Anil K Rustgi; J Alan Diehl; Constantinos Koumenis; Hallgeir Rui; Serge Y Fuchs
Journal:  Cancer Cell       Date:  2017-02-13       Impact factor: 31.743

4.  CD8+ T Cell Priming in Established Chronic Viral Infection Preferentially Directs Differentiation of Memory-like Cells for Sustained Immunity.

Authors:  Laura M Snell; Bethany L MacLeod; Jaclyn C Law; Ivan Osokine; Heidi J Elsaesser; Kebria Hezaveh; Russell J Dickson; Marc A Gavin; Cynthia J Guidos; Tracy L McGaha; David G Brooks
Journal:  Immunity       Date:  2018-10-09       Impact factor: 31.745

5.  Primary tumors induce neutrophil extracellular traps with targetable metastasis promoting effects.

Authors:  Roni F Rayes; Jack G Mouhanna; Ioana Nicolau; France Bourdeau; Betty Giannias; Simon Rousseau; Daniela Quail; Logan Walsh; Veena Sangwan; Nicholas Bertos; Jonathan Cools-Lartigue; Lorenzo E Ferri; Jonathan D Spicer
Journal:  JCI Insight       Date:  2019-07-25

6.  Natural interferon-alpha in combination with melphalan/prednisone versus melphalan/prednisone in the treatment of multiple myeloma stages II and III: a randomized study from the Myeloma Group of Central Sweden.

Authors:  A Osterborg; M Björkholm; M Björeman; G Brenning; K Carlson; F Celsing; G Gahrton; G Grimfors; H Gyllenhammar; R Hast
Journal:  Blood       Date:  1993-03-15       Impact factor: 22.113

7.  Searching for pathogenic gene functions to cervical cancer.

Authors:  Woong Shick Ahn; Su Mi Bae; Joon Mo Lee; Sung Eun Namkoong; Sei-Jun Han; Young Lae Cho; Gye Hyun Nam; Jeong-Sun Seo; Chong Kook Kim; Yong-Wan Kim
Journal:  Gynecol Oncol       Date:  2004-04       Impact factor: 5.482

8.  Loss of TGFbeta signaling destabilizes homeostasis and promotes squamous cell carcinomas in stratified epithelia.

Authors:  Géraldine Guasch; Markus Schober; H Amalia Pasolli; Emily Belmont Conn; Lisa Polak; Elaine Fuchs
Journal:  Cancer Cell       Date:  2007-10       Impact factor: 31.743

9.  Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway.

Authors:  Yu Kato; Kimiyo Tabata; Takayuki Kimura; Ayako Yachie-Kinoshita; Yoichi Ozawa; Kazuhiko Yamada; Junichi Ito; Sho Tachino; Yusaku Hori; Masahiro Matsuki; Yukiko Matsuoka; Samik Ghosh; Hiroaki Kitano; Kenichi Nomoto; Junji Matsui; Yasuhiro Funahashi
Journal:  PLoS One       Date:  2019-02-27       Impact factor: 3.240

10.  Mutation-Derived Neoantigens for Cancer Immunotherapy.

Authors:  John C Castle; Mohamed Uduman; Simarjot Pabla; Robert B Stein; Jennifer S Buell
Journal:  Front Immunol       Date:  2019-08-07       Impact factor: 7.561

View more
  9 in total

Review 1.  Myeloid cell-targeted therapies for solid tumours.

Authors:  Sangeeta Goswami; Swetha Anandhan; Deblina Raychaudhuri; Padmanee Sharma
Journal:  Nat Rev Immunol       Date:  2022-06-13       Impact factor: 53.106

2.  Engaging Pattern Recognition Receptors in Solid Tumors to Generate Systemic Antitumor Immunity.

Authors:  Michael Brown
Journal:  Cancer Treat Res       Date:  2022

3.  Pre-encoded responsiveness to type I interferon in the peripheral immune system defines outcome of PD1 blockade therapy.

Authors:  Giselle M Boukhaled; Ramy Gadalla; Heidi J Elsaesser; Diala Abd-Rabbo; Rene Quevedo; S Y Cindy Yang; Mengdi Guo; Ben X Wang; Babak Noamani; Diana Gray; Sally C M Lau; Kirsty Taylor; Kyaw Aung; Anna Spreafico; Aaron R Hansen; Samuel D Saibil; Naoto Hirano; Cynthia Guidos; Trevor J Pugh; Tracy L McGaha; Pamela S Ohashi; Adrian G Sacher; Marcus O Butler; David G Brooks
Journal:  Nat Immunol       Date:  2022-07-14       Impact factor: 31.250

4.  Uncovering the mode of action of engineered T cells in patient cancer organoids.

Authors:  Johanna F Dekkers; Maria Alieva; Astrid Cleven; Farid Keramati; Amber K L Wezenaar; Esmée J van Vliet; Jens Puschhof; Peter Brazda; Inez Johanna; Angelo D Meringa; Heggert G Rebel; Maj-Britt Buchholz; Mario Barrera Román; Amber L Zeeman; Sam de Blank; Domenico Fasci; Maarten H Geurts; Annelisa M Cornel; Else Driehuis; Rosemary Millen; Trudy Straetemans; Mara J T Nicolasen; Tineke Aarts-Riemens; Hendrikus C R Ariese; Hannah R Johnson; Ravian L van Ineveld; Froso Karaiskaki; Oded Kopper; Yotam E Bar-Ephraim; Kai Kretzschmar; Alexander M M Eggermont; Stefan Nierkens; Ellen J Wehrens; Henk G Stunnenberg; Hans Clevers; Jürgen Kuball; Zsolt Sebestyen; Anne C Rios
Journal:  Nat Biotechnol       Date:  2022-07-25       Impact factor: 68.164

5.  Targeted Modulation of Interferon Response-Related Genes with IFN-Alpha/Lambda Inhibition.

Authors:  Debpali Sur; Katerina Leonova; Bar Levi; Shany Ivon Markowitz; Raichel Cohen-Harazi; Ilya Gitlin; Katerina Gurova; Andrei Gudkov; Albert Pinhasov; Igor Koman; Elimelech Nesher
Journal:  Int J Mol Sci       Date:  2022-06-29       Impact factor: 6.208

6.  In situ vaccination using unique TLR9 ligand K3-SPG induces long-lasting systemic immune response and synergizes with systemic and local immunotherapy.

Authors:  Hirokazu Okada; Ken Takahashi; Hiroaki Yaku; Kouji Kobiyama; Keiko Iwaisako; Xiangdong Zhao; Masahiro Shiokawa; Norimitsu Uza; Yuzo Kodama; Ken J Ishii; Hiroshi Seno
Journal:  Sci Rep       Date:  2022-02-08       Impact factor: 4.996

Review 7.  Type-I Interferon Signaling in Fanconi Anemia.

Authors:  Karima Landelouci; Shruti Sinha; Geneviève Pépin
Journal:  Front Cell Infect Microbiol       Date:  2022-02-07       Impact factor: 5.293

8.  Editorial: Cytokine and cytokine receptor-based immunotherapies: Updates, controversies, challenges, and future perspectives.

Authors:  Jun Wang; Brent Johnston; Pedro Berraondo
Journal:  Front Immunol       Date:  2022-07-26       Impact factor: 8.786

Review 9.  The pleiotropic roles of cGAS-STING signaling in the tumor microenvironment.

Authors:  Jun Li; Samuel F Bakhoum
Journal:  J Mol Cell Biol       Date:  2022-08-05       Impact factor: 8.185

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.